Humira use in pJIA extended

The licence for Humira (adalimumab) in polyarticular juvenile idiopathic arthritis (pJIA) has been extended to include the treatment of children from 4 years-old. Humira can be given in combination with methotrexate when the response to one or more DMARDs is inadequate, or as monotherapy if methotrexate is inappropriate or not tolerated.

The recommended dose is 24mg/m2 (max 40mg) by subcutaneous injection every other week. To enable accurate dosing, Humira solution for injection is now available as a vial, in addition to the prefilled pen and syringe presentations.

View Humira drug record

Further Information: Abbott Laboratories Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...

An older man in a blue shirt and beige trousers leans forward on a sofa rubbing his painful lower back. Promoted
MIMSconnect

Established muscle relaxant offers new approach to managing back pain

Sponsored by Mibe Pharma

A muscle relaxant that has been used for decades outside the UK may provide an alternative to current treatments for low back pain, explains Dr Sunny Nayee, consultant in anaesthesia and pain medicine at Imperial College NHS Healthcare Trust.

Sponsored by Mibe Pharma UK Ltd. UK/MYO/21/044; December 2021.

Click here to view prescribing information for Myopridin® (pridinol mesilate)